Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 118 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depressive Episode Clear all
Not listed Phase 3 Interventional

Transcranial Magnetic Stimulation (TMS) for Suicidal Ideation

NCT01212848
View directory record Official record
Conditions
Depressive Episode, Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation - Sham Comparator
Device
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Bethesda, Maryland • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Jul 21, 2026, 11:30 AM EDT
Enrolling by invitation No phase listed Observational

Youth Depression and Suicide Research Network

NCT04572321
View directory record Official record
Conditions
Depression, Suicide, Suicidal Ideation, Suicide, Attempted, Depressive Disorder, Depressive Symptoms, Depressive Episode, Depression and Suicide, Depression, Teen, Depression, Anxiety
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 20 Years
Enrollment
5,000 participants
Timeline
2020 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 11:30 AM EDT
Terminated Not applicable Interventional

Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology

NCT05461599
View directory record Official record
Conditions
Depressive Symptoms, Major Depressive Disorder, Depression, Cardiology, Gastrointestinal Diseases, Depressive Disorder, Depressive Episode, Adolescent Behavior, Adolescent - Emotional Problem
Interventions
SparkRx Mobile App
Device
Lead sponsor
Limbix Health, Inc.
Industry
Eligibility
13 Years to 22 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Jul 21, 2026, 11:30 AM EDT
Completed Phase 3 Interventional

A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder

NCT00232414
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Jul 21, 2026, 11:30 AM EDT
Terminated Phase 4 Interventional

Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder

NCT03537547
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Disorder, Depressive Episode, Depression, Unipolar
Interventions
GeneSight Psychotropic test, FDA-approved antidepressant or antipsychotic treatment
Other · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Jul 21, 2026, 11:30 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

NCT02670538
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
42
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Jul 21, 2026, 11:30 AM EDT
Recruiting Not applicable Interventional

tDCS: Sleep to Mood in Depression (S2M-D)

NCT07572526
View directory record Official record
Conditions
Major Depressive Disorder, MDD, Depression, Major Depressive Episode
Interventions
transcranial direct current stimulation (tDCS)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 11:30 AM EDT
Completed Not applicable Interventional Results available

Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder

NCT03288714
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Depressive Episode, Major Depressive Disorder
Interventions
Synchronized Transcranial Magnetic Stimulation (sTMS), Sham Stimulation
Device
Lead sponsor
Wave Neuroscience
Industry
Eligibility
22 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jul 21, 2026, 11:30 AM EDT
Recruiting Not applicable Interventional

Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression

NCT07127913
View directory record Official record
Conditions
Bipolar II Disorder, Bipolar II Disorder, Most Recent Episode Major Depressive
Interventions
Device: Stimulation-ON, Device: Stimulation-OFF, Device: Stimulation -ON Active Control
Device
Lead sponsor
Andrew Krystal
Other
Eligibility
22 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jul 21, 2026, 11:30 AM EDT
Completed Not applicable Interventional Results available

Electroconvulsive Therapy Amplitude Titration

NCT04621786
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface
Device
Lead sponsor
University of New Mexico
Other
Eligibility
50 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Jul 21, 2026, 11:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder

NCT00596622
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium
Drug
Lead sponsor
Indiana University
Other
Eligibility
15 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Jul 21, 2026, 11:30 AM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension for GLYX13-C-202, NCT01684163

NCT02192099
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Rapastinel (225 mg/450 mg IV administration)
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 21, 2026, 11:30 AM EDT
Completed No phase listed Observational Results available

Treatment-Resistant Depression Registry

NCT00320372
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
55
States / cities
Tucson, Arizona • Beverly Hills, California • Garden Grove, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jul 21, 2026, 11:30 AM EDT
Terminated Phase 4 Interventional Results available

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

NCT04203056
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
Interventions
Aripiprazole Lauroxil, ARI-ORAL, AL-NCD
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jul 21, 2026, 11:30 AM EDT
Terminated Phase 2Phase 3 Interventional

The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition

NCT03693105
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
Interventions
Active SAINT Stimulation, Sham SAINT Stimulation
Device
Lead sponsor
Magnus Medical
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Iowa City, Iowa • Manhattan, New York • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Jul 21, 2026, 11:30 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder

NCT01677182
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
41
States / cities
Birmingham, Alabama • Anaheim, California • Glendale, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Jul 21, 2026, 11:30 AM EDT
Completed Not applicable Interventional Results available

Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder

NCT03716869
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Episode
Interventions
Universal Screening Arm
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Not listed
Enrollment
12,909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Jul 21, 2026, 11:30 AM EDT
Completed Phase 4 Interventional Results available

Prevention of Relapse & Recurrence of Bipolar Depression

NCT00961961
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium / Fluoxetine, Lithium / Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 21, 2026, 11:30 AM EDT
Completed Not applicable Interventional

Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes

NCT03289923
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Sham TMS + Cognitive therapy, Active TMS + Cognitive therapy
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 21, 2026, 11:30 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

NCT05227209
View directory record Official record
Conditions
Depressive Episodes, Bipolar I Depression
Interventions
SEP-4199 CR
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Huntsville, Alabama • Anaheim, California • Imperial, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jul 21, 2026, 11:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine for Suicidality in Bipolar Depression

NCT01944293
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Episode, Suicidal Ideation
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Jul 21, 2026, 11:30 AM EDT
Terminated No phase listed Observational

The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

NCT04753385
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Not listed
Lead sponsor
LivaNova
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
33
States / cities
Birmingham, Alabama • Costa Mesa, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Jul 21, 2026, 11:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

NCT00672620
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
38
States / cities
Beverly Hills, California • Irvine, California • Santa Ana, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 21, 2026, 11:30 AM EDT
Completed Not applicable Interventional

The RAFT ECT Study

NCT05402657
View directory record Official record
Conditions
Major Depressive Episode
Interventions
Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
Procedure
Lead sponsor
The George Institute
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Augusta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 21, 2026, 11:30 AM EDT